{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:42:43Z","timestamp":1791650563944,"version":"4.3.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T00:00:00Z","timestamp":1711584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T00:00:00Z","timestamp":1711584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21H03070"],"award-info":[{"award-number":["21H03070"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019356","name":"SGH Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019356","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Kenzo Suzuki Memorial Foundation"},{"DOI":"10.13039\/100007428","name":"Naito Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006724","name":"Japanese Urological Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006724","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s11523-024-01047-y","type":"journal-article","created":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T11:01:39Z","timestamp":1711623699000},"page":"401-410","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4157-1929","authenticated-orcid":false,"given":"Taizo","family":"Uchimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuya","family":"Tsuchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Komura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Fukuokaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Hirasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuhiko","family":"Yoshizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanobu","family":"Saruta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoru","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Higashio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Tsujino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ko","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyosuke","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shutaro","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Iwatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Urabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Yanagisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Tsuduki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Takahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruo","family":"Inamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Miki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutoshi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"Shiroki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotsugu","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhito","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,28]]},"reference":[{"issue":"17","key":"1047_CR1","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","volume":"18","author":"H von der Maase","year":"2000","unstructured":"von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068\u201377.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1047_CR2","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015\u201326.","journal-title":"N Engl J Med"},{"issue":"10031","key":"1047_CR3","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909\u201320.","journal-title":"Lancet"},{"issue":"4","key":"1047_CR4","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1817323","volume":"381","author":"Y Loriot","year":"2019","unstructured":"Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019;381(4):338\u201348.","journal-title":"N Engl J Med"},{"issue":"12","key":"1047_CR5","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Duran I, Lee JL, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384(12):1125\u201335.","journal-title":"N Engl J Med"},{"issue":"7","key":"1047_CR6","first-page":"400","volume":"18","author":"P Sidaway","year":"2021","unstructured":"Sidaway P. Sacituzumab govitecan is safe and effective. Nat Rev Clin Oncol. 2021;18(7):400.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"1047_CR7","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s11523-022-00872-3","volume":"17","author":"D Sigorski","year":"2022","unstructured":"Sigorski D, Rozanowski P, Izycka-Swieszewska E, Wiktorska K. Antibody-drug conjugates in uro-oncology. Target Oncol. 2022;17(3):203\u201321.","journal-title":"Target Oncol"},{"issue":"4","key":"1047_CR8","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/bju.15893","volume":"131","author":"T Uchimoto","year":"2023","unstructured":"Uchimoto T, Fukushima T, Komura K, Fukuokaya W, Adachi T, Hashimoto T, et al. Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinoma. BJU Int. 2023;131(4):477\u201385.","journal-title":"BJU Int"},{"key":"1047_CR9","doi-asserted-by":"publisher","first-page":"320","DOI":"10.5694\/j.1326-5377.1964.tb115781.x","volume":"2","author":"B Gandevia","year":"1964","unstructured":"Gandevia B, Tovell A. Declaration of Helsinki. Med J Aust. 1964;2:320\u20131.","journal-title":"Med J Aust"},{"issue":"2","key":"1047_CR10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"3","key":"1047_CR11","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143\u201352.","journal-title":"Lancet Oncol"},{"issue":"11","key":"1047_CR12","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1200\/JCO.2009.25.4599","volume":"28","author":"J Bellmunt","year":"2010","unstructured":"Bellmunt J, Choueiri TK, Fougeray R, Schutz FA, Salhi Y, Winquist E, et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol. 2010;28(11):1850\u20135.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1047_CR13","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","volume":"22","author":"C Dumontet","year":"2023","unstructured":"Dumontet C, Reichert JM, Senter PD, Lambert JM, Beck A. Antibody-drug conjugates come of age in oncology. Nat Rev Drug Discov. 2023;22(8):641\u201361.","journal-title":"Nat Rev Drug Discov"},{"issue":"22","key":"1047_CR14","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1200\/JCO.20.03489","volume":"39","author":"ST Tagawa","year":"2021","unstructured":"Tagawa ST, Balar AV, Petrylak DP, Kalebasty AR, Loriot Y, Flechon A, et al. TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol. 2021;39(22):2474\u201385.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1047_CR15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3892\/mco.2021.2253","volume":"14","author":"N Furubayashi","year":"2021","unstructured":"Furubayashi N, Hori Y, Morokuma F, Tomoda T, Negishi T, Inoue T, et al. Paclitaxel and carboplatin chemotherapy after platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinoma. Mol Clin Oncol. 2021;14(5):91.","journal-title":"Mol Clin Oncol."},{"key":"1047_CR16","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.ejca.2018.09.002","volume":"104","author":"G Gravis","year":"2018","unstructured":"Gravis G, Billon E, Baldini C, Massard C, Hilgers W, Delva R, et al. Unexpected response to cisplatin rechallenge after immune checkpoint inhibitors in patients with metastatic urothelial carcinoma refractory to platinum regimen. Eur J Cancer. 2018;104:236\u20138.","journal-title":"Eur J Cancer"},{"issue":"2","key":"1047_CR17","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.eururo.2017.08.022","volume":"73","author":"B Szabados","year":"2018","unstructured":"Szabados B, van Dijk N, Tang YZ, van der Heijden MS, Wimalasingham A, Gomez de Liano A, et al. Response rate to chemotherapy after immune checkpoint inhibition in metastatic urothelial cancer. Eur Urol. 2018;73(2):149\u201352.","journal-title":"Eur Urol"},{"key":"1047_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/11795549211021667","volume":"15","author":"M Bersanelli","year":"2021","unstructured":"Bersanelli M, Buti S, Cortellini A, Bandini M, Banna GL, Pederzoli F, et al. Clinical outcomes of patients with metastatic urothelial carcinoma after progression to immune checkpoint inhibitors: a retrospective analysis by the Meet-Uro Group (Meet-URO 1 study). Clin Med Insights Oncol. 2021;15:1\u201310.","journal-title":"Clin Med Insights Oncol"},{"issue":"12","key":"1047_CR19","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/iju.15300","volume":"30","author":"S Taguchi","year":"2023","unstructured":"Taguchi S, Kawai T, Ambe Y, Kishitani K, Sugimoto K, Miyakawa J, et al. Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: a multicenter propensity score-matched study. Int J Urol. 2023;30(12):1180\u20136.","journal-title":"Int J Urol"},{"issue":"2","key":"1047_CR20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41585-020-00394-5","volume":"18","author":"EI Heath","year":"2021","unstructured":"Heath EI, Rosenberg JE. The biology and rationale of targeting nectin-4 in urothelial carcinoma. Nat Rev Urol. 2021;18(2):93\u2013103.","journal-title":"Nat Rev Urol"},{"issue":"4","key":"1047_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.188902","volume":"1878","author":"S Qiu","year":"2023","unstructured":"Qiu S, Zhang J, Wang Z, Lan H, Hou J, Zhang N, et al. Targeting Trop-2 in cancer: recent research progress and clinical application. Biochim Biophys Acta Rev Cancer. 2023;1878(4): 188902.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"1047_CR22","doi-asserted-by":"crossref","unstructured":"Nishimura K, Nishio K, Hirosuna K, Komura K, Hayashi T, Fukuokaya W, et al. Efficacy of pembrolizumab and comprehensive CD274\/PD-L1 profiles in patients previously treated with chemoradiation therapy as radical treatment in bladder cancer. J Immunother Cancer. 2022;10(1):e003868.","DOI":"10.1136\/jitc-2021-003868"},{"issue":"1","key":"1047_CR23","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12943-023-01897-6","volume":"22","author":"K Komura","year":"2023","unstructured":"Komura K, Hirosuna K, Tokushige S, Tsujino T, Nishimura K, Ishida M, et al. The impact of FGFR3 alterations on the tumor microenvironment and the efficacy of immune checkpoint inhibitors in bladder cancer. Mol Cancer. 2023;22(1):185.","journal-title":"Mol Cancer"},{"issue":"4","key":"1047_CR24","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun A, de Reynies A, Allory Y, Sjodahl G, Robertson AG, Seiler R, et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol. 2020;77(4):420\u201333.","journal-title":"Eur Urol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01047-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-024-01047-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01047-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T13:20:34Z","timestamp":1716384034000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-024-01047-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,28]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["1047"],"URL":"https:\/\/doi.org\/10.1007\/s11523-024-01047-y","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,28]]},"assertion":[{"value":"26 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kazumasa Komura was partially supported by Grant-in-Aid No. 21H03070 (Japan Society for the Promotion of Science: JSPS), the Kenzo Suzuki Memorial Foundation, the SGH Foundation, the Naito Memorial Foundation, and the Cancer Translational Research Foundation of Japanese Urological Association (JUA).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Taizo Uchimoto, Shuya Tsuchida, Kazumasa Komura, Wataru Fukuokaya, Takahiro Adachi, Yosuke Hirasawa, Takeshi Hashimoto, Atsuhiko Yoshizawa, Masanobu Saruta, Mamoru Hashimoto, Takuya Higashio, Takuya Matsuda, Kazuki Nishimura, Takuya Tsujino, Ko Nakamura, Tatsuo Fukushima, Kyosuke Nishio, Shutaro Yamamoto, Kosuke Iwatani, Fumihiko Urabe, Keiichiro Mori, Takafumi Yanagisawa, Shunsuke Tsuduki, Kiyoshi Takahara, Teruo Inamoto, Jun Miki, Kazutoshi Fujita, Takahiro Kimura, Yoshio Ohno, Ryoichi Shiroki, Hirotsugu Uemura, and Haruhito Azuma declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was approved by the Institutional Review Board (IRB) from Osaka Medical and Pharmaceutical University (approval number: RIN-750-2571, approved on 24th January 2020). This observational study adhered to ethical principles aligned with the Declaration of Helsinki, the International Conference on Harmonisation\u2019s Good Clinical Practice guidelines, Good Pharmacoepidemiology Practices, and relevant laws for noninterventional and observational studies.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"The data from this study can be accessed by academic and commercial partners upon a reasonable request, subject to IRB approval and a data use agreement. For further details or to reanalyze the study\u2019s data, contact the Lead Contact at kazumasa.komura@ompu.ac.jp.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"T. Uchimoto: conceptualization, data curation, analysis, investigation, methodology, software, visualization, writing original draft, supervision. S. Tsuchida: data curation, analysis, investigation, methodology, software, visualization. K. Komura: data curation, investigation, investigation, writing the original draft, supervision. W. Fukuokaya: investigation, data curation, validation. A. Adachi: validation, methodology. Y. Hirasawa: methodology, validation. T. Hashimoto: methodology, validation. A. Yoshizawa: data curation. M. Saruta: data curation. M. Hashimoto: analysis. T. Higashio: data curation, analysis. T. Matsuda: investigation. K. Nishimura: data curation. T. Tsujino: methodology, data curation. K. Nakamura: investigation. T. Fukushima: data curation, analysis. K. Nishio: validation. S. Yamamoto: data curation. K. Iwatani: investigation, supervision. F. Urabe: investigation, validation, supervision. K. Mori: methodology, data analysis. T. Yanagisawa: investigation. S. Tsuduki: writing original draft, review. K, Takahara: editing, supervision. T. Inamoto: data curation. J. Miki: data curation, analysis. K. Fujita: review and editing, supervision. T. Kimura: investigation, validation, supervision. Y. Ohno: supervision. R. Shiroki: supervision. H. Uemura: supervision. H. Azuma: supervision.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}